Long-term use of osteoporosis medication may reduce bone fracture risk for some patients

May 10, 2012 By Leland Kim
This spine X-ray shows a patient who has osteoporosis.

(Medical Xpress) -- Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it. Based on available evidence, a UCSF researcher reevaluated his 2006 finding from a randomized 10-year study of alendronate, a type of bisphosphonate – a class of drugs that prevent loss of bone mass.

“Our study suggests that even after five years of therapy, if your bone density is low enough, you’re at high risk for having additional spine fractures,” said Dennis Black, PhD, professor and division chief of UCSF’s Department of Epidemiology and Biostatistics’ Clinical Trials and Multicenter Studies. “And by continuing this therapy for these patients, it’s likely to decrease that risk for spine fractures.”

The study was funded by Merck, the maker of Fosamax, a commercial version of alendronate.

Osteoporosis is responsible for 1.5 million fractures in the United States a year at a cost of $14 billion annually. As many as half of all women and a quarter of men older than 50 will break a bone due to osteoporosis, according to the National Institutes of Health.

Balancing Risks vs. Benefits

Treating with bisphosphonates, particularly for more than five years, has been linked to some side effects, including atypical . Public concerns led the U.S. Food and Drug Administration (FDA) to hold a hearing last September about the drug. The organization is expected to publish its guidelines in the New England Journal of Medicine (NEJM) this week, alongside Black’s perspective.

“Any decrease in spine fracture risk will need to be balanced against a possible but unknown increase in other side effects including atypical femur fractures,” Black said.

“It is clearly established that three to five years of bisphosphonates are beneficial in reducing fractures, particularly in women with existing low bone density,” he added. “However, whether treatment should continue after five years has been controversial. I think the FDA is going to say that there’s limited data that continuing bisphosphonates long-term will further reduce fracture risk, and many people can safely discontinue after three to five years.”

Black hopes his perspective will give physicians and patients specific information about who might benefit by continuing and specifically what that benefit might be.

Studying Risk of Spine Fracture

The original study by Black and colleagues studied a total of 6,459 women for up to five years, comparing alendronate to a placebo. That study showed less of spine, hip and other major bones and led to FDA approval of alendronate in 1997.

In a newer 2006 continuation study, 1,099 of the women who had taken alendronate for an average of five years at the start of the continuation study were randomly assigned to five more years of alendronate or a placebo. Those who continued on alendronate showed lower risk of spine fractures but no difference in risk for non-spine and hip fractures.

“Our study suggests that at least for women who are at very high risk for spine fractures, they will benefit by continuing alendronate therapy to decrease the number of spine fractures,” Black said.

Elevated public concerns about the possible link between alendronate and femur fractures, as well as other such as osteonecrosis of the jaw – bone death caused by poor blood supply to the area – have compelled the FDA to address the issue this week. While the FDA perspective includes information about possible risks of long-term use, Black’s study specifically examined long term fracture benefits.

“Each patient and her physician need to weigh the benefits versus the risks, but the purpose of our analysis was to try to give people a sense of what the benefits might be and in whom they would be highest,” Black said.

The study by Black and colleagues examined one type of bisphosphonate: alendronate. The drug had been developed and the studies funded by Merck, which sold the drug under the name Fosamax. In 2008, alendronate became generic and now is most commonly used in generic form. Black cautioned that other bisphosphonates including risedronate and ibandronate, have not been studied long-term with respect to their benefits for those with previous spine fractures.

Black is the first author of the paper; the senior author is Clifford J. Rosen, MD, of the Maine Medical Center Research Institute; co-authors include Ann V. Schwartz, PhD, of the UCSF Department of Epidemiology and Biostatistics; Douglas Bauer, MD, of the UCSF Department of Medicine; and Steven R. Cummings, MD, of California Pacific Medical Center.

The original and continuation studies were carried out from 1991 to 2004 by Black and colleagues at UCSF with funding to UCSF from Merck. The current analysis published in the New England Journal Perspective was performed independently of commercial sponsorship and the sponsor did not have any input in this analysis.

Explore further: Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half

Related Stories

Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half

February 8, 2012
There is growing evidence that supports an association between atypical fractures of the femur– a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance ...

Recommended for you

Scientists develop infection model for tickborne flaviviruses

August 22, 2017
National Institutes of Health (NIH) scientists have filled a research gap by developing a laboratory model to study ticks that transmit flaviviruses, such as Powassan virus. Powassan virus was implicated in the death of a ...

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Novel approach to track HIV infection

August 18, 2017
Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions—infectious particles—to be connected to infectivity.

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.